The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of ovarian function suppression of 3-monthly versus monthly GnRH agonist as endocrine therapy for premenopausal breast cancer patients.
 
Daniella Audi Blotta
No Relationships to Disclose
 
Jessica Ribeiro Gomes
Honoraria - AstraZeneca
 
Shermann Brandão Rodrigues Moreira
No Relationships to Disclose
 
Danielle Fortes Colosimo
No Relationships to Disclose
 
Carolina Cavalcanti Gonçalves Ferreira
No Relationships to Disclose
 
Elaine Aparecida Forgiarini
No Relationships to Disclose
 
Debora De Melo Gagliato
Honoraria - AstraZeneca; Daiichi Sankyo/Lilly; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - Daiichi Sankyo/Lilly; Lilly; Pfizer; Roche/Genentech; Teva
Research Funding - Novartis
Travel, Accommodations, Expenses - AstraZeneca; Libbs; Roche; Roche; Roche
 
Antonio C. Buzaid
Stock and Other Ownership Interests - Agenus
Honoraria - AstraZeneca; Blau; BMS Brazil; Dr. Reddy's Laboratories; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech; United Medical
Consulting or Advisory Role - AstraZeneca; Blau Farmaceutica; BMS Brazil; Dr. Reddy's Laboratories; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech; United Medical
Speakers' Bureau - AstraZeneca; BMS Brazil; Dr. Reddy's Laboratories; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech; United Medical
Research Funding - AstraZeneca (Inst); BMS Brazil (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - BMS Brazil; MSD Oncology; Novartis; Pfizer; Roche